SCHEMBL30748798

SCHEMBL30748798

CC1(C)C(=O)N(c2cnc(C3CCOCC3)nc2)c2nc(CO)nc(NC3CCC3)c21

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 15/20 0.33
SYK P43405 1/20 0.32
BTK Q06187 1/20 0.31
MERTK Q12866 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748918 0.82 TAF1 (0.34) SYK
SCHEMBL31691334 0.81 HDAC6 (0.34) MAPK1SYK
SCHEMBL30749150 0.78 SYK (0.41) MAPK1SYK
SCHEMBL30748947 0.75 PDE8B (0.32) MAPK1
SCHEMBL30748728 0.73 BTK (0.35) SYKBTK
SCHEMBL30749139 0.73 MAOB (0.41) SYKBTK
SCHEMBL30749004 0.71 HDAC6 (0.33) MAPK1SYK
SCHEMBL30748933 0.70 SYK (0.40) MAPK1SYK
SCHEMBL30748787 0.70 L3MBTL1 (0.36) MAPK1SYK
SCHEMBL30748916 0.70 HDAC6 (0.34) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPK1 2929/4885SYK 2316/4885BTK 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.